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Background: Lead, mercury, cadmium and arsenic are some of the most common toxic metals to which
Canadians are exposed. The effect of exposure to current low levels of toxic metals on fetal growth
restriction is unknown.
Objective: The aim of this study was to examine relationships between exposure to lead, mercury,
cadmium and arsenic during pregnancy, and risk of small for gestational age (SGA) birth.
Methods: Lead, mercury, cadmium and arsenic levels were measured in blood samples from the ﬁrst
and third trimesters in 1835 pregnant women from across Canada. Arsenic species in ﬁrst trimester urine
were also assessed. Relative risks and 95% conﬁdence intervals were estimated using log binomial
multivariate regression. Important covariates including maternal age, parity, pre-pregnancy BMI, and
smoking, were considered in the analysis. An exploratory analysis was performed to examine potential
effect modiﬁcation of these relationships by single nucleotide polymorphisms (SNPs) in GSTP1 and
GSTO1 genes.
Results: No association was found between blood lead, cadmium or arsenic and risk for SGA. We ob-
served an increased risk for SGA for the highest compared to the lowest tertile of exposure for mercury
(41.6 mg/L, RR¼1.56.; 95% CI¼1.04–2.58) and arsenobetaine (42.25 mg/L, RR¼1.65; 95% CI¼1.10–2.47)
after adjustment for the effects of parity and smoking. A statistically signiﬁcant interaction was observed
in the relationship between dimethylarsinic acid (DMA) levels in urinary arsenic and SGA between strata
of GSTO1 A104A (p for interaction¼0.02). A marginally signiﬁcant interaction was observed in the re-
lationship between blood lead and SGA between strata of GSTP1 A114V (p for interaction¼0.06).
Conclusions: These results suggest a small increase in risk for SGA in infants born to women exposed to
mercury and arsenic. Given the conﬂicting evidence in the literature this warrants further investigation
in other pregnant populations.
Crown Copyright & 2015 Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Pregnant women and their fetuses are especially susceptible to
the effects of exposure to a variety of environmental toxicants
including lead, mercury, cadmium, and arsenic.
Metals are ubiquitous in the environment, and exposure occurs
through ingestion of food, water, soil, or dust; inhalation from air;
and through direct contact with consumer products (Health Ca-
nada, 2004, 2008, 2006). Some known consequences of high levelevier Inc. This is an open access ar
, Healthy Environments and
e Dr., AL 0801A, Ottawa, ON,
uckle).exposures to these metals in the general population include:
neurological deﬁcits, cancer, renal impairment, convulsions, coma,
and bone disease (Jarup, 2003; Duruibe et al., 2007). Only a few
guidelines exist for metals (e.g., methylmercury) (Legrand et al.,
2010), with more research needed on potential health effects, if
any, of exposure to the low levels of metals to which most of the
general Canadian populations are exposed.
Physiologic changes that occur during pregnancy can alter
toxicokinetics and toxicodynamics of environmental chemicals,
such as metals, in the pregnant woman’s body. For example, bone
resorption to help meet calcium demands can increase during
pregnancy (Kovacs and Kronenberg, 1997) and release cumulative
lead stores from bone into circulation resulting in an endogenous
source of prenatal exposure (Gulson et al., 2003; Manton et al.,ticle under the CC BY-NC-ND license
S. Thomas et al. / Environmental Research 140 (2015) 430–439 4312003; Téllez-Rojo et al., 2004). Increased maternal plasma volume,
body fat, and body water, coupled with increased excretion, are
designed for optimal nutrient supply and waste removal from the
fetus (Mattison et al., 1991). However, little is known about the
impact of these changes on metabolism and excretion of these
substances during pregnancy and lactation, but they likely will
differ depending on the chemical class or nature of the substance.
Pregnancy is a period of dynamic growth and change for the de-
veloping embryo and fetus, thus, any insults to the in utero en-
vironment could result in suboptimal fetal development (Rice and
Barone, 2000).
Growth restricted fetuses fail to reach their full genetic growth
potential due to a decreased nutrient supply from the utero pla-
cental circulation (Cetin et al., 2004). Intrauterine growth restric-
tion (IUGR) manifests as small for gestational age (SGA), deﬁned as
an infant weighing less than the 10th percentile for their gesta-
tional age and sex (Canadian Institute for Health Information,
2009). Size relative to gestational age is an established predictor of
early childhood mortality and morbidity (Rahman et al., 2009).
Children who are born SGA are more likely to have birth compli-
cations and are at increased risk for excessive weight gain, cardi-
ovascular disease and insulin resistance syndrome later in life
(Clayton et al., 2007). Metals are potential risk factors for SGA
births, and are hypothesized to induce growth restriction through
oxidative stress mediated pathways (Myatt, 2006). Speciﬁcally,
when toxic metals are present in the maternal bloodstream, they
may cause abnormal placental function and impair nutrient
transport to the fetus through the indirect formation of reactive
oxygen species (ROS) and reactive nitrogen species (RNS) that
cause oxidative stress by reacting with macromolecules and da-
maging them. When the vascular endothelium is damaged, en-
dothelins are released, causing the smooth muscle around the
blood vessels to contract. This vasoconstriction causes maternal
blood pressure to increase and decreases the blood ﬂow to the
fetus (Pollock and Pollock, 2005). This reduced blood ﬂow may
cause ischemic damage, which could lead to fetal growth restric-
tion and subsequent low birthweight (Llanos and Ronco, 2009).
The elimination half-lives of mercury, lead and cadmium in
blood are 18 days, 30 days and 100 days respectively (Bernard,
1995). These metals are cumulative toxicants, and previous ex-
posure can be detected after long periods of non-exposure (Ber-
nard, 1995). A proportion of lead in the blood may be presentTable 1
Distribution of metal exposure in study population (n¼1835).
Below LODa N (%) Minimum 25th
Blood
Lead (mg/dL) 0 (0) 0.17 0.43
Cadmium (mg/L) 11 (0.6) oLOD 0.13
Mercury (mg/L) 141 (7.1) oLOD 0.32
Arsenic (mg/L) 48 (2.5) oLOD 0.51
Urine
DMA(mg As/L) 261 (14.6) oLOD 1.1
Arsenobetaine (mg As/L) 917 (51.2) oLOD oL
MMA (mg As/L) 1654 (92.4) oLOD oL
Arsenate (mg As/L) 1506 (84.1) oLOD oL
Arsenite (mg As/L) 1762 (98.4) oLOD oL
DMA (mg As/L )b 261 (14.6) oLOD 1.6
Arsenobetaine (mg As/L )b 917 (51.2) oLOD oL
MMA (mg As/L)b 1654 (92.4) oLOD oL
Arsenate (mg As/L)b 1506 (84.1) oLOD oL
Arsenite (mg As/L)b 1762 (98.4) oLOD oL
a Limits of detection in blood: lead (0.10 mg/dL ), cadmium (0.04 mg/L ), mercury (0
(0.75 mg As/L).
b Adjusted for speciﬁc gravity.because of bone remodeling mobilizing lead that has been stored
from previous exposure (Smith et al., 2002). In contrast, inorganic
arsenic is rapidly cleared from blood. In humans, it has a half-life
of 10 h (Hughes, 2006). Measurement of urinary arsenic levels is
generally accepted as the most reliable indicator of recent arsenic
exposure, given that arsenic absorbed from the lungs or the gas-
trointestinal tract is excreted in the urine within one to two days,
while arsenic is cleared from blood within a few hours (ASTDR,
2007). However some papers have shown good correlation be-
tween urinary and blood arsenic (Hall et al., 2006).
The effects of lead, cadmium, mercury and arsenic have all been
studied to varying degrees in the context of their effect on fetal
growth outcomes such as small for gestational age (SGA) and low
birthweight (LBW). In general, the literature regarding metal ex-
posure and fetal growth outcomes is inconsistent. Some studies
report an association (Rahman et al., 2009; Llanos and Ronco,
2009; Bellinger et al., 1991; Chen et al., 2006; Foldspang and
Hansen, 1990; Hopenhayn et al., 2003; Kippler et al., 2011; Lee
et al., 2010; Lin et al., 2011; Nishijo et al., 2004; Odland et al., 1999;
Osman et al., 2000; Ramón et al., 2009; Shirai et al., 2010; Tian
et al., 2009; Xie et al., 2013; Yang et al., 2003; Zhu et al., 2010)
while others report no association (Odland et al., 1999; Osman
et al., 2000; Ding et al., 2013; Daniels et al., 2007; Galicia-García
et al., 1997; Jones et al., 2010; Sowers et al., 2002; Menai et al.,
2012; Loiacono et al., 1992; Lucas et al., 2004). Few studies have
examined low-level exposure as currently experienced in most
developed countries such as Canada, thus any resultant health
effects are relatively unknown. The aim of this study was to ex-
amine relationships between exposures to lead (Pb), mercury (Hg),
cadmium (Cd) (as measured in blood) or arsenic (As) (as measured
in blood and urine) during pregnancy and the risk of small for
gestational age birth. Single nucleotide polymorphisms (SNPs) in
GSTP1 and GSTO1 genes were explored as a potential modiﬁer of
the relationship between lead, cadmium, mercury or arsenic and
SGA.2. Methods
2.1. Study population
The Maternal–Infant Research on Environmental Chemicalspercentile 50th percentile 75th percentile Maximum
0.59 0.81 4.04
0.20 0.30 4.65
0.64 1.19 6.80
0.75 1.13 33.00
2.4 4.5 64.4
OD oLOD 3.4 1573.0
OD oLOD oLOD 11.2
OD oLOD oLOD 24.0
OD oLOD oLOD 22.5
2.4 3.8 44.1
OD 1.0 37.7 889.1
OD oLOD oLOD 7.7
OD oLOD 0.8 24.1
OD oLOD oLOD 15.6
.12 mg/L), arsenic (0.23 mg/L); and in urine: DMA (0.75 mg As/L) and arsenobetaine
Table 2
Relative risk of SGA according to maternal characteristics.
Risk factor SGA (%) Total
births
Crude RR (95%
CI)
Adjusted RR
(95% CI)a
Age
o29 36 (6.3) 568 Reference
30–35 33 (5.1) 644 0.81 (0.51–
1.28)
36þ 37 (5.9) 623 0.94 (0.60–
1.46)
Ethnicity
White
Not White
83 (5.6) 1,496 Reference
23 (6.8) 339 1.22 (0.78–
1.91)
Country of birth
Foreign
Canadian
25 (7.2) 348 Reference
81 (5.5) 1487 0.76 (0.49–
1.17)
Parity
0 65 (8.1) 802 Reference
1þ 41 (4.0) 1,031 0.49 (0.34–
0.72)
0.51 (0.35–
0.74)
Education
College/trade diploma
or less
38 (5.5) 691 Reference
Undergraduate degree 36 (5.4) 673 0.97 (0.62–
1.52)
Graduate degree 32 (6.8) 469 1.24 (0.79–
1.96)
Household Income
$100 000 or more 36 (5.1) 708 Reference
$70,001–100,000 31 (6.0) 514 1.19 (0.74–
1.89)
$40,001– $70,000 19 (6.2) 305 1.23 (0.71–
2.10)
o$40,000 13 (5.8) 222 1.15 (0.62–
2.13)
Marital status
Married or common law 97 (5.5) 1,747 Reference
Single 9 (10.2) 88 1.84 (0.96–
3.52)
Pre-pregnancy BMI
Underweight or normal 72 (6.6) 1,085 Reference
Overweight or obese 25 (4.1) 613 0.61 (0.39–
0.96)
Smoking during pregnancy
Never 59 (5.2) 1,129 Reference
Former 27 (5.5) 487 1.06 (0.68–
1.65)
1.08 (0.70–
1.67)
Current 20 (9.2) 218 1.80 (1.08–
2.85)
1.72 (1.07–
2.77)
Alcohol consumption
No alcohol 76 (5.5) 1,379 Reference
Any alcohol 22 (7.6) 289 1.38 (0.87–
2.18)
a This column contains results for covariates included in the ﬁnal model (parity
and smoking) using backward selection (p-valueo0.15).
Table 3
Association between metal exposure and SGA.
SGA n
(%)
Total births
N
Crude RR
(95 CI%)
Adjusted RR
(95 CI%)a
Lead
o0.52 mg/dL 35 (4.7) 744 Reference Reference
0.52–1.04 mg/dL 57 (6.6) 862 1.41 (0.93–
2.12)
1.33 (0.88–1.99)
41.04 mg/dL 14 (6.1) 229 1.30 (0.71–
2.37)
1.19 (0.65–2.18)
Mercury
o0.8 mg/L 59 (5.4) 1,086 Reference Reference
0.8–1.6 mg/L 23 (4.8) 479 0.88 (0.55–
1.41)
0.89 (0.55–1.42)
41.6 mg/L 24 (8.9) 270 1.64 (1.04–
2.56)
1.56 (1.04–2.58)
Cadmiumb
o0.15 mg/L 31 (5.2) 593 Reference Reference
0.15–0.3 mg/L 44 (5.5) 804 1.05 (0.67–
1.64)
1.00 (0.64–1.56)
40.3 mg/L 31 (7.1) 438 1.35 (0.84–
2.19)
1.26 (0.78–2.04)
Arsenic
o0.525 mg/L 30 (6.0) 498 Reference Reference
0.525 –1.05 mg/L 42 (5.1) 818 0.85 (0.54–
1.34)
0.85 (0.54–1.34)
41.05 mg/L 34 (6.6) 519 1.09 (0.68–
1.75)
1.08 (0.68–1.74)
DMA
o1.87 mg As/L 40 (6.5) 612 Reference Reference
1.87–3.75 mg As /L 19 (4.2) 453 0.77 (0.43–
1.37)
0.74 (0.42–1.32)
43.75 mg As /L 43 (5.9) 726 1.23 (0.69–
2.22)
1.18 (0.66–2.12)
Arsenobetaine
o0.75 mg As/L 46 (4.8) 958 Reference Reference
0.75–2.25 mg As/L 9 (5.1) 177 1.14 (0.56–
2.28)
1.20 (0.60–2.41)
42.25 mg As/L 47 (7.2) 656 1.64 (1.10–2.47) 1.65 (1.10–2.47)
a Adjusted for the effect of smoking and parity; DMA and arsenobetaine also
adjusted for speciﬁc gravity.
b Analysis of cadmium exposure is not adjusted for smoking.
S. Thomas et al. / Environmental Research 140 (2015) 430–439432(MIREC) Study is a prospective cohort study, described in detail
elsewhere (Arbuckle et al., 2013) and summarized here. Between
2008 and 2011, 2001 pregnant women were recruited in the ﬁrst
trimester of pregnancy from 10 study sites across Canada. Exclu-
sion criteria included: inability to communicate and consent in
either French or English, greater than 14 weeks gestation at the
time of recruitment, less than 18 years of age, diagnosed with a
fetal anomaly or a history of major chronic disease. Excluded from
this analysis are: 18 women who withdrew during the study, 51
women who gave birth to multiples, 9 stillbirths, 32 spontaneous
abortions, 13 therapeutic abortions, 28 with no metal exposure
data, and 15 with no infant sex, weight, or gestational age re-
corded. The ﬁnal sample size for this analysis was 1835 mother–
infant pairs.
2.2. Metals exposure
Maternal blood was collected during the ﬁrst and third trime-
sters of pregnancy and analyzed for total lead, cadmium, mercury,
and arsenic concentrations. Speciated levels of arsenic (arsenite
(Asþ3) (generally considered to be of most toxicological sig-
niﬁcance (Hughes, 2006)), arsenate (Asþ5), monomethylarsenic
Table 4
Gene–environment interaction in relation to risk for SGA.
GSTP1 A114V¼ CC GSTP1 A114V ¼TCþTT
SGA (%) Not SGA (%) Adjusted RR SGA (%) Not SGA (%) Adjusted RR
Pb40.08 lg/dL 24 (5.3) 430 (94.7) 0.90 (0.57–1.41) Pb40.08 lg/dL 9 (14.3) 54 (85.7) 2.25 (0.95–5.16)
Pbr0.08 lg/dL 62 (5.6) 1050 (94.4) Reference Pbr0.08 lg/dL 11 (6.2) 167 (93.8) Reference
P for interaction 0.06
Cd40.30 lg/L 24 (5.9) 383 (94.1) 1.06 (0.67–1.68) Cd40.30 lg/L 7 (12.5) 49 (87.5) 1.69 (0.71–4.00)
Cdr 0.30 lg/L 62 (5.4) 1097 (94.7) Reference Cdr 0.30 lg/L 13 (7.0) 172 (93.0) Reference
P for interaction 0.35
Hg41.20 lg/L 31 (7.7) 372 (92.3) 1.65 (1.08–2.52)
Reference
Hg41.20 lg/L 5 (10.4) 43 (89.6) 1.24 (0.47–3.22)
Reference
Hgr1.20 lg/L 55 (4.7) 1108 (95.3) Hgr1.20 lg/L 15 (7.8) 178 (92.2)
P for interaction¼0.59
As 40.79 lg/L 36 (4.8) 711 (95.2) 0.77 (0.51–1.17) As 40.79 lg/L 9 (8.9) 92 (91.1) 1.12 (0.48–2.56)
Asr0.79 lg/L 50 (6.1) 769 (93.9) Reference Asr0.79 lg/L 11 (7.9) 129 (92.1) Reference
P for interaction ¼0.45
DMA41.50 lg As/L 24 (4.8) 472 (95.2) 0.87 (0.55–1.38) DMA41.50 lgAs/L 8 (10.4) 69 (89.6) 1.32 (0.57–3.08)
DMAr1.50 lg As/L 58 (5.6) 977 (94.4) Reference DMAr1.50 lg As/L 12 (7.6) 145 (92.4) Reference
P for interaction¼0.39
AsBe 45.64 lg As/L 41 (6.4) 598 (93.6) 1.43 (0.94–2.18) AsBe 45.64 lg As/L 11 (11.8) 82 (88.2) 1.77 (0.77–4.8)
AsBe r5.64 lg As/L 41 (4.6) 851 (95.4) Reference AsBe r5.64 lg As/L 9 (6.4) 132 (93.6) Reference
P for interaction¼0.66
GSTP1 I105V ¼ AA GSTP1 I105V¼ AGþGG
SGA (%) Not SGA (%) Adjusted RR SGA (%) Not SGA (%) Adjusted RR
Pb40.08lg/dL 17 (7.3) 217 (92.7) 1.22 (0.69–2.15) Pb40.08lg/dL 16 (5.7) 266 (94.3) 0.95 (0.54–1.66)
Pbr0.08 lg/dL 31 (5.6) 526 (94.4) Reference Pbr0.08 lg/dL 42 (5.7) 691 (94.3) Reference
P for interaction¼0.53
Cd40.30 lg/L 17 (8.3) 188 (91.7) 1.51 (0.86–2.66) Cd40.30 lg/L 14 (5.5) 243 (94.5) 0.90 (0.50–1.61)
Cdr 0.30 lg/L 31 (5.3) 555 (94.7) Reference Cdr0.30 lg/L 44 (5.8) 714 (94.2) Reference
P for interaction¼0.21
Hg 4 1.20 lg/L 20 (9.6) 188 (90.4) 1.98 (1.15–3.43) Hg 4 1.20lg/L 16 (6.6) 227 (93.4) 1.21 (0.69–2.11)
Hg r 1.20 lg/L 28 (4.8) 555 (95.2) Reference Hgr1.20 lg/L 42 (5.4) 730 (94.6) Reference
P for interaction 0.23
As40.79 lg/L 23 (5.9) 366 (94.1) 0.93 (0.54–1.60) As40.79 lg/L 22 (4.8) 437 (95.2) 0.73 (0.44–1.22)
Asr0.79 lg/L 25 (6.2) 377 (93.8) Reference Asr0.79 lg/L 36 (6.5) 520 (93.5) Reference
P for interaction¼0.53
DMA41.50 lg As/L 17 (6.9) 231 (93.2) 1.23 (0.70–2.19) DMA41.50 lg As/L 15 (4.6) 310 (95.4) 0.76 (0.43–1.35)
DMAr1.50 lg As/L 30 (5.7) 497 (94.3) Reference DMAr1.50 lg As/L 40 (6.0) 624 (94.0) Reference
P for interaction¼0.24
AsBe45.64lg As/L 24 (7.4) 299 (92.6) 1.54 (0.89–2.67) AsBe45.64 lg As/L 28 (6.8) 381 (93.2) 1.46 (0.88–2.43)
AsBer5.64 lg As/L 23 (5.1) 429 (94.9) Reference AsBer5.64 lg As/L 27 (4.7) 553 (95.3) Reference
P for interaction¼0.89
GSTO1 A104A ¼CC GSTO1 A104A¼CAþAA
SGA (%) Not SGA (%) Adjusted RR SGA (%) Not SGA (%) Adjusted RR
Pb40.08 lg/L 15 (5.7) 248 (94.3) 0.94 (0.52–1.69) Pb40.08 lg/dL 18 (7.1) 235 (92.9) 1.20 (0.70–2.06)
Pbr0.08 lg/dL 36 (5.6) 609 (94.4) Reference Pbr0.08 lg/dL 37 (5.8) 604 (94.2) Reference
P for interaction¼ 0.54
Cd40.30 lg/L 18 (7.9) 210 (92.1) 1.55 (0.89–2.70) Cd40.30 lg/L 13 (5.5) 222 (94.5) 0.84 (0.46–1.54)
Cdr 0.30 lg/L 33 (4.8) 647 (95.2) Reference Cdr 0.30 lg/L 42 (6.4) 617 (93.6) Reference
P for interaction ¼0.14
Hg41.20 lg/L 19 (8.0) 218 (92.0) 1.70 (0.98-2.93) Hg41.20 lg/L 17 (7.9) 197 (92.1) 1.47 (0.85–2.55)
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S. Thomas et al. / Environmental Research 140 (2015) 430–439434acid (MMA), dimethylarsinic acid (DMA), and arsenobetaine
(AsBe)) were measured in urine samples collected during the ﬁrst
trimester. Samples were analyzed using inductively-coupled
plasma mass spectrometry by the Toxicology Laboratory of the
Institut National de Santé Publique du Québec (INSPQ). The de-
tection limits for this study were as follows: Blood Pb (0.10 mg/dL),
Cd (0.04 mg/L), total Hg (0.12 mg/L), As (0.225 mg/L). The limit of
detection for all arsenic metabolites in urine was 0.75 mg As/L.
Results below the limit of detection (LOD) were assigned a value of
half of the LOD. As there is uncertainty about the critical trimester
of exposure for fetal growth, various studies have averaged con-
taminant concentrations across pregnancy (e.g. Valvi et al., 2015;
Mora et al., 2015). Blood metal concentrations were based on the
average of the ﬁrst and third trimester measures if both were
available. If only one measure was available, then that measure
was used. To account for variation in urine dilution due to dis-
parity in sampling, temperature, physical activity and ﬂuid intake
(Suwazono et al., 2008), speciﬁc gravity was included as a cov-
ariate in the regression model.
2.3. Single nucleotide polymorphisms
Epidemiological and in vitro studies have suggested that GSTP1
may play a role in mercury and arsenic toxicokinetics (Custodio
et al., 2004; Goodrich and Basu, 2012; Gundacker et al., 2010;
Marcos et al., 2006). The two SNPs under investigation (GSTP1
A114V and GSTP1 I105V) are known to alter enzyme activity
(Strange et al., 2000; Suzuki et al., 1987). Epidemiological studies
using biomarkers have found associations between GSTP1 poly-
morphisms and differential metabolism/elimination of arsenic and
mercury (Custodio et al., 2004; Goodrich and Basu, 2012; Gun-
dacker et al., 2010; Marcos et al., 2006). GSTO1 is suspected to play
a role in arsenic biotransformation. More speciﬁcally, GSTO1 has
been shown to catalyse the reduction of monomethylarsonic
(MMA), the rate-limiting step in arsenic detoxiﬁcation (Zakharyan
et al., 2001), making it a candidate gene in the modiﬁcation of
arsenic exposure and SGA. The GSTO1 A104A SNP has been shown
to affect the functional activity of the enzyme (Punia et al., 2011).
Double stranded DNA concentration was assessed using the
Quant-it PicoGreen assay (Invitrogen). Brieﬂy, PicoGreen dye was
added to each well. Following this, the ﬂuorescent signal of the
sample was measured and plotted against the standard DNA
concentration used to make a standard curve.
2.4. Birth outcomes
As part of the MIREC study, each baby’s length (cm) and weight
(g) at birth were abstracted from a medical chart review. Gesta-
tional age (weeks) was derived using both the woman’s last
menstrual period (LMP) and ultrasound dating. For this analysis,
LMP is the preferred method for estimating gestational age since
ultrasound methods rely on fetal size to estimate gestational age
(Nardozza et al., 2012). If the two methods differed by 47 days,
then gestational age was determined using ultrasound due to
concerns over recall and reliability of the LMP estimate. SGA births
were identiﬁed as those weighing less than the 10th percentile for
a reference population based on the same completed week of
gestation and infant sex (Kramer et al., 2001).
2.5. Covariates
This analysis considered the effects of established predictors of
SGA: age, parity, ethnicity, country of origin, household income,
education, smoking status, pre-pregnancy BMI, and marital status.
Information on these factors was collected by questionnaire dur-
ing the ﬁrst trimester of pregnancy.
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Spearman’s correlation coefﬁcients were calculated to examine
the relationship between the ﬁrst and third trimester blood con-
centrations of the metals. Relative risks and 95% conﬁdence in-
tervals controlling for important covariates were estimated using
log binomial regression. A parsimonious covariate model predict-
ing SGAwas created using backward stepwise deletion at a p-value
of 0.15. Relative risks for each metal were adjusted for this cov-
ariate model.
Smoking is the single most important known predictor of SGA
(McCowan and Horgan, 2009; Valero De Bernabé et al., 2004), and
so should be considered; however, this analysis is complicated by
the fact that cigarette smoke is also a major source of cadmium
exposure. Including smoking in a model may obscure any effect of
cadmium on SGA. Therefore the effect of cadmiumwas modeled in
three ways: with and without controlling for smoking, and by
excluding smokers from the analysis. All analysis was performed
using SAS enterprise guide version 4.2.3. Results
Lead, cadmium, mercury and arsenic were detectable in the
blood of 100%, 99%, 93% and 97% of participants respectively (Ta-
ble 1). In maternal urine DMA and arsenobetaine were detectable
in 85% and 49% of the sample. Since arsenate, arsenite, and MMA
were not detectable in 485% of the study population, they were
not included in the analysis of SGA.
First and third trimester concentrations of lead, mercury and
cadmium in maternal blood were signiﬁcantly and highly corre-
lated with coefﬁcients of 0.74, 0.63 and 0.79, respectively. The
correlation coefﬁcient for arsenic in blood between ﬁrst and third
trimester was 0.21.
3.1. Factors associated with SGA
Table 2 describes the characteristics of the study population,
bivariate analysis between the covariates and SGA, and the re-
lationships with covariates included in the ﬁnal parsimonious
model. Among the births, 5.8% were SGA. Mothers in this study
were mostly white, never smokers, Canadian born and of higher
socioeconomic status. Infant gender was 52.7% male and 47.3%
female. Independent of other factors, only parity and smoking
were associated with SGA. Parous women had a decreased risk for
a SGA birth (RR¼0.51, 95% CI¼0.35–0.74) compared to nulliparous
women. Smoking at any time during pregnancy was associated
with a 72% increased risk of SGA birth (RR 1.72, 95% CI 1.07–2.77).
Pre-pregnancy BMI was associated with decreased risk of SGA (RR
0.61, 95% CI 0.39–0.96); however, this association was not sig-
niﬁcant when other factors were considered.
3.2. Relationship between metal exposure and SGA
Mercury and arsenobetaine exposures were each associated
with increased risk for SGA with relative risks for highest versus
lowest exposure tertiles: 1.56 (95% CI 1.04–2.58) and 1.65 (95% CI
1.10–2.47) respectively (Table 3). No relationship was observed
between blood lead or arsenic and SGA. The relative risk of SGA
from moderate and high exposure to cadmium were close to the
null value when adjusted for smoking (0.15–0.3 mg/L: RR¼0.97)
(95% CI: 0.62–1.52); 40.3 mg/L: RR¼1.03 (95% CI: 0.60–1.78).
Cadmium was also not a signiﬁcant risk factor for SGA when
smoking was not adjusted for or when smokers were excluded
from the analysis.3.3. Exploratory gene–environment interactions
The GSTP1 and GSTO1 genes have never been studied in the
context of fetal growth prior to this analysis. Stronger relative risks
were hypothesized in genotype categories with decreased detox-
iﬁcation capacity. The relative risks of SGA for DMA exposure
differed across strata deﬁned by the GSTO1 A104A SNP (p-value
interaction 0.02). The relative risk for those with a variant allele
was in the direction of increased risk (RR¼1.48 95% CI 0.87–2.51),
while the relative risk for those with a homozygous wildtype
genotype was in the direction of a protective effect (RR¼0.56 95%
CI 0.29–1.08). There was a marginally signiﬁcant interaction be-
tween lead exposure and the GSTP1 A114V SNP (p¼0.06) (Table 4).
No other interactions approached statistical signiﬁcance.4. Discussion
In the MIREC Study detectable levels of lead, cadmium, mer-
cury and arsenic were found in ﬁrst and third trimester blood
samples for over 90% of women. This is an indication of the sen-
sitivity of the analytical method used and not an indication of any
increased risk. The median blood lead (0.59 mg/dL) and arsenic
(0.75 mg/L) concentrations in this analysis were lower than those
reported in the general population of Canadian women aged 20–
39 in the Canadian Health Measures Survey (CHMS) (0.83 mg/dL,
0.88 mg/L, respectively), but fairly consistent with the measures for
mercury (0.64 vs. 0.69 mg/L in the CHMS) and cadmium (0.2 vs.
0.28 mg/L in the CHMS) (Health Canada, 2010, 2013). Blood lead,
cadmium or arsenic at the levels observed in this study were not
associated with increased risk of SGA.
Women in the highest tertile of mercury exposure (41.6 mg/L)
had an increased risk for SGA infants. In vitro studies have shown
that mercury can interfere with nutrient transfer across the pla-
centa (Urbach et al., 1992). Mercury has a very high afﬁnity for
fetal hemoglobin (Jedrychowski et al., 2006) and methylmercury
can quickly be transported into the fetal bloodstream through the
neutral amino acid carrier system (Kajiwara et al., 1996). Several
epidemiological studies have reported an association between
mercury and birth weight (Foldspang and Hansen, 1990; Lee et al.,
2010; Ramón et al., 2009). However, later analysis of a more
complete dataset disproved Foldspang and Hansen's (1990) origi-
nal ﬁndings (Bjerregaard and Hansen, 1996),and the analysis
by Ramón et al. (2009) lacked statistical power. Only two of the
previous studies of mercury exposure and SGA have had sample
sizes greater than 1000 (Daniels et al., 2007; Hujoel et al., 2005).
Of the studies that reported geometric mean concentrations of
mercury in blood, all 5 (Lee et al., 2010; Ding et al., 2013; Guo et al.,
2013; Lederman et al., 2008; Bjerregaard and Hansen, 2000) have
higher exposure levels than those seen in the MIREC sample
(geometric mean¼0.57 mg/L). Of the studies examining the re-
lationship between mercury and SGA, four used measures of
mercury in both cord blood and maternal blood (Lee et al., 2010;
Guo et al., 2013; Lederman et al., 2008; Bjerregaard and Hansen,
2000). The remaining studies of mercury and SGA looked at
mercury in cord blood, cord tissue, or amalgam ﬁllings, and did not
use maternal blood. Differences in the associations reported in
these studies may in part be due to these differences in exposure
matrices.
Several small studies have reported an association between
urinary arsenic (primarily inorganic) and birthweight, including a
study in Bangladesh (Rahman et al., 2009), in Romania (Gelmann
et al., 2013), in New Hampshire USA (Fei et al., 2013), However, no
signiﬁcant association between urinary arsenic levels and SGA was
reported in a study in Japan (Shirai et al., 2010). We found urinary
arsenobetaine levels 42.25 mg As/L to be associated with an
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excreted in urine and is perceived to be less toxic than inorganic
arsenic (Vahter, 2009; Francesconi, 2010). There is no literature to
suggest that arsenobetaine would be related to fetal size in-
dependent of other arsenic metabolites. A study in rats reported
no teratogenic or deleterious effects of arsenobetaine by gavage on
reproductive development (Taylor et al., 2013). It is possible that
this association was due to chance, or that urinary arsenobetaine
concentrations are a proxy for an unknown risk factor that is truly
associated with SGA. There have been no studies to date of asso-
ciations between individual urinary arsenic metabolites and SGA.
In the MIREC study, arsenobetaine was measured in a spot
urine sample collected during the ﬁrst trimester, without seafood
abstinence. This sample may not represent long-term exposure to
arsenic as arsenobetaine is thought to have a very short half-life in
urine and is excreted rapidly and unchanged in urine (Lai et al.,
2004). Arsenobetaine was detected in almost half the women in
MIREC and when it was detected it was at relatively elevated le-
vels. Confusion remains on how to interpret arsenobetaine con-
centrations in urine. While correlations have been reported be-
tween ﬁsh and shellﬁsh consumption and urinary concentrations
(Lovreglio et al., 2012; Rivera-Núñez et al., 2012), one study of
volunteers fed a diet with no known sources of arsenobetaine
suggested that either accumulated arsenobetaine in the tissues
was slowly released over time or that arsenobetaine is a human
metabolite of dimethylarsinic acid or inorganic arsenic from the
trial food, or both (Newcombe et al., 2010). The authors hypothe-
sized that the long-term excretion pattern was dependent on the
individual volunteer. Data from another feeding study indicated
that arsenobetaine may be formed as a result of biotransformation
of other organic arsenicals of seafood origin and reported large
individual variations in the estimated absorption and excretion of
arsenobetaine that depended on the dietary source (Molin et al.,
2014).
We found no association with maternal cadmium exposure and
SGA. When smokers are included in the analysis, there is no sig-
niﬁcant effect on SGA both before and after controlling for the
effect of smoking. When smokers are removed from the dataset,
there are very few people in the high exposure category. This is to
be expected as smokers have much higher blood cadmium levels
than nonsmokers. Because of this, the risk estimate between the
highest and lowest exposure groups in this analysis has such a
wide conﬁdence interval that this risk estimate and dose response
pattern are difﬁcult to interpret. The results of these three analyses
do not support the case for an association between cadmium ex-
posure and SGA, independent of smoking status.
Maternal blood, cord blood, placental tissue and urine are all
matrices that have been used to study the association between
cadmium exposure and fetal growth. This fact may be a con-
tributing factor to the conﬂicting ﬁndings in the literature re-
garding cadmium exposure and fetal growth. Cadmium con-
centrations in blood are likely to be more transient in nature than
urinary levels, reﬂecting recent exposure and may not be as di-
rectly correlated with the key toxic responses (World Health Or-
ganization, 2001; Hays et al., 2008). Two studies found no effect of
cadmium on fetal growth outcomes (Odland et al., 1999; Loiacono
et al., 1992) while others found relationships with birth weight or
length (Kippler et al., 2011; Nishijo et al., 2004; Tian et al., 2009;
Galicia-García et al., 1997). Most studies of cadmium exposure and
SGA have similar exposure ranges as the MIREC sample, however
2 studies in Taiwan (Lin et al., 2011; Tian et al., 2009) and one in
Bangladesh (Kippler et al., 2011) had exposure ranges higher than
those observed in this study. Many of these studies had very small
sample sizes; only one analysis (Kippler et al., 2011) was larger
than 1000 subjects.
Lead has been extensively studied using a variety of matrices(Andrews et al., 1994), with most of the more recent studies of the
relationship with SGA using maternal blood, cord blood and pla-
centa. Multiple studies have found an association with SGA (Chen
et al., 2006; Odland et al., 1999; Xie et al., 2013; Gundacker et al.,
2010; Jelliffe-Pawlowski et al., 2006; Berkowitz et al., 2006; Gon-
zález-Cossío et al., 1997) while others report no relationship
(Shirai et al., 2010; Jones et al., 2010; Sowers et al., 2002). The
different matrices used and the varying exposure levels may ex-
plain the conﬂicting results. The lead exposure in the Taiwanese
study (Chen et al., 2006) was very high, with a maximum exposure
of 62 mg/dL. Studies conducted in the U.S. (Bellinger et al., 1991;
Zhu et al., 2010; Jones et al., 2010; Sowers et al., 2002; Jelliffe-
Pawlowski et al., 2006; Berkowitz et al., 2006) and in Nordic
countries (Osman et al., 2000; Odland et al., 2004) had levels of
exposure closer to those measured in the MIREC study, with
maximum exposure levels ranging from 10 to 12 mg/dL (still
considerably higher than the levels in the MIREC cohort). Only the
Taiwanese study had a sample size greater than 1000 (Chen et al.,
2006). Two studies have had sample sizes greater than 4000
(Bellinger et al., 1991; Berkowitz et al., 2006).
An examination of potential interactions of metal concentra-
tions and the GSTP1 and GSTO1 genes on the risk of SGA found a
signiﬁcant interaction between DMA levels and the GSTO1 A104A
SNP, as well as a marginally signiﬁcant interaction between blood
lead concentrations and the GSTP1 A114V SNP. The GSTO1 enzyme
has been shown to catalyse the reduction of MMA, the rate-lim-
iting step in arsenic detoxiﬁcation (Zakharyan et al., 2001), making
it a candidate enzyme in the modiﬁcation of arsenic exposure and
SGA. If the effect of lead on SGA is real, but only certain sub-
populations are at risk for this effect, then genetic variation may
be the reason that some studies report signiﬁcant associations
while others do not. Epidemiological studies using biomarkers
have found associations between GSTP1 polymorphisms and dif-
ferential metabolism/elimination of arsenic, mercury and lead
(Custodio et al., 2004; Goodrich and Basu, 2012; Gundacker et al.,
2010; Marcos et al., 2006; Gundacker et al., 2009). One study
found GSTP1 to have no effect on fetal growth (Yamada, 2004),
however the study simply compared frequencies using a ﬁsher’s
exact test, and genotype was analyzed as the exposure rather than
an effect modiﬁer of a relationship with an environmental
exposure.
4.1. Methodological considerations
The participation rate in the original study was relatively low at
only 39% (Arbuckle et al., 2013). A comparison of the sample to
Canadian birth statistics reveals that the MIREC participants ten-
ded to be older, more educated, included a greater proportion of
married or common law, had fewer smokers and higher household
income than the general Canadian pregnant population from 2009
(Arbuckle et al., 2013; Public Health Agency of Canada, 2009).
Despite the fact that the sample was not representative of the
Canadian population of pregnant women, the ﬁndings of this
study are generalizable to this, and other pregnant populations
with similar metal exposure. The relationship being studied is a
biologic one and thus it should hold in a population that is not
demographically identical.
The low correlation observed between the ﬁrst and third tri-
mester measures of arsenic in blood is in line with existing lit-
erature. It has been shown that arsenic is cleared from the blood
rapidly (Hughes, 2006), which means that blood arsenic may not
accurately represent arsenic exposure over the course of preg-
nancy. This is a limitation of using blood arsenic as an exposure
measure. A limitation of the urinary arsenic results is that with the
high detection limit for the inorganic species, especially MMA, we
were not able to examine risks from the sum of the inorganic
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There is inherent misclassiﬁcation in the use of SGA as a sur-
rogate measure of fetal growth restriction. Speciﬁcally, not all in-
fants who are SGA are pathologically growth restricted, and not all
infants who are pathologically growth restricted are SGA (Mayer
and Joseph, 2012). This misclassiﬁcation is likely to be non-dif-
ferential based on infants’ metal exposure in utero.
Another area of uncertainty is the critical period(s) during
pregnancy that can affect fetal growth and therefore when ex-
posure to metals should be measured. Fetal weight gain is fastest
in the third trimester (Matheus and Sala, 1980); however the de-
termination of the fetus’ centile of weight could occur before this
period. Similarly, the exact timing for the programming of length
is unclear (Norris and Cameron, 2013).
There is possible uncontrolled confounding in this analysis due
to lack of information on maternal diet. Dietary factors such as
milk and leafy green consumption have been shown to have a
positive effect on fetal growth outcomes (Mayer and Joseph, 2012).
Maternal under-nutrition is associated with IUGR (Wu et al., 2012),
but this is likely not an issue in this study of Canadian women of
relatively high socioeconomic status. Of more relevance is ma-
ternal over-nutrition, or obesity during/prior to pregnancy, which
can also result in IUGR (Wu et al., 2012). While this analysis does
not account for nutritional factors, it does examine pre-pregnancy
BMI, which may capture some of the variation caused by in-
dividual differences in diet. Furthermore, the trace element deﬁ-
ciencies that are associated with IUGR are not typical of people
living in developed countries, especially in our sample of pregnant
women who are older, more educated, and of higher socio-
economic status. All of these characteristics make them more
likely to start prenatal care earlier, to have more prenatal visits,
and to take prenatal dietary supplements (Public Health Agency of
Canada, 2009).4.2. Implications
The results indicate that neither blood lead, cadmium nor ar-
senic at the levels typical of Canadian exposure have a signiﬁcant
measurable effect on birth size by gestational age. However, higher
concentrations of maternal blood mercury or urinary arsenobe-
taine may be associated with increased risk of a fetal growth re-
stricted infant. Furthermore, the null ﬁndings of this study do not
mean that high levels of these metals are not associated with SGA
births.
There is some inconsistency in the existing literature regarding
mercury exposure and fetal size and no previous human studies
have examined arsenobetaine risks. Canadians are generally ex-
posed to mercury in their diet, primarily from certain types of ﬁsh
(Health Canada, 2007). A strong correlation exists between ﬁsh
and shellﬁsh consumption and urinary arsenobetaine concentra-
tions (Rivera-Núñez et al., 2012) and a seafood intervention study
has reported that arsenobetaine was the major arsenical excreted
followed by DMA (Molin et al., 2014). Arsenobetaine has also been
detected in edible mushrooms and hares from contaminated sites
in Canada (Koch et al., 2013).
The risk of mercury and arsenobetaine exposure from ﬁsh and
shellﬁsh must be weighed against the beneﬁts of ﬁsh consumption
on fetal growth. Fish is an excellent source of omega-3 fatty acids,
protein, naturally occurring Vitamin D, and other essential mi-
nerals (Health Canada, 2007) that help the fetus to grow. By fol-
lowing ﬁsh consumption advice, Canadians can reduce their ex-
posure to these metals while enjoying the health beneﬁts of eating
ﬁsh (Health Canada, 2007).5. Conclusions
Increased exposure to mercury and arsenobetaine were asso-
ciated with increased risk of giving birth to a SGA infant in the
MIREC cohort of Canadian women. These ﬁndings, in addition to
previous work in this area, underscore the need to monitor
pregnant populations and to raise education and awareness
around chemicals and health (particularly with respect to ﬁsh
consumption) amongst this target population. Further research is
needed to conﬁrm the associations we observed between these
metals and fetal growth restriction,Acknowledgements
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